Medical Oncology

, 32:203 | Cite as

Dysregulated expression of Dicer in invasive ductal breast carcinoma

  • Ali Akbar Poursadegh Zonouzi
  • Azim Nejatizadeh
  • Mohammad Rahmati-Yamchi
  • Hedieh Fardmanesh
  • Samira Shakerizadeh
  • Ahmad Poursadegh Zonouzi
  • Kazem Nejati-Koshki
  • Mohammad ShekariEmail author
Original Paper


Several lines of evidence suggest that the global down-regulation of the microRNAome (miRNAome) involved in pathogenesis of various malignancies. Impaired microRNAs processing pathway is one possible mechanism for global down-regulation of the miRNAome. Dicer is a key enzyme in miRNA processing pathway, and dysregulation of its expression has been suggested as a possible cause of miRNAome alterations observed in various cancers. However, Dicer mRNA expression in invasive ductal breast carcinoma (IDC) has not been investigated in depth. Therefore, this study aimed to evaluate the mRNA expression of Dicer in IDC and also to assess the correlation of its expression with clinicopathological parameters including age, histological grade, tumor size and lymph node metastasis. We investigated the expression of the Dicer in seventy fresh invasive ductal breast carcinomas and matched adjacent non-neoplastic tissue by quantitative real-time PCR using validated reference genes. In addition, the possible impact of clinicopathological characteristics on Dicer expression levels was analyzed. Our results showed that Dicer mRNA expression is down-regulated in slightly more than half (51.43 %) of the tumor specimens when compared to adjacent non-neoplastic tissue. Comparison of the Dicer expression level between tumor and matched adjacent non-neoplastic tissue showed that there is no statistical significant differences between them (P = 0.425). We also found that Dicer mRNA expression in IDC samples was not correlated with clinicopathological features. In conclusion, our findings provide additional evidence to support the hypothesis that Dicer expression down-regulated in breast cancer. This study suggested that the decreased expression of Dicer may be potential underlying mechanism in pathogenesis of IDC.


MiRNA MiRNA processing machinery Dicer Invasive ductal breast carcinoma 



The authors would like to express our sincerest appreciation to all the subjects for participating in this study.

Conflict of interest

There are no potential conflicts of interest for each author, concerning the submitted manuscript.


  1. 1.
    Escalona S, Blasco JA, Reza MM, Andradas E, Gomez N. A systematic review of FDG-PET in breast cancer. Med Oncol. 2010;27(1):114–29.PubMedCrossRefGoogle Scholar
  2. 2.
    Salimi M, Mozdarani H, Majidzadeh K. Expression pattern of ATM and cyclin D1 in ductal carcinoma, normal adjacent and normal breast tissues of Iranian breast cancer patients. Med Oncol. 2012;29(3):1502–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Nardone A, Corvigno S, Brescia A, D’Andrea D, Limite G, Veneziani BM. Long-term cultures of stem/progenitor cells from lobular and ductal breast carcinomas under non-adherent conditions. Cytotechnology. 2011;63(1):67–80.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Zeng RC, Zhang W, Yan XQ, Ye ZQ, Chen ED, Huang DP, et al. Down-regulation of miRNA-30a in human plasma is a novel marker for breast cancer. Med Oncol. 2013;30(1):477.PubMedCrossRefGoogle Scholar
  5. 5.
    Osaki M, Takeshita F, Ochiya T. MicroRNAs as biomarkers and therapeutic drugs in human cancer. Biomarkers. 2008;13(7):658–70.PubMedCrossRefGoogle Scholar
  6. 6.
    Martello G, Rosato A, Ferrari F, Manfrin A, Cordenonsi M, Dupont S, et al. A MicroRNA targeting dicer for metastasis control. Cell. 2010;141(7):1195–207.PubMedCrossRefGoogle Scholar
  7. 7.
    Hata A, Lieberman J. Dysregulation of microRNA biogenesis and gene silencing in cancer. Sci Signal. 2015;8(368):re3.PubMedCrossRefGoogle Scholar
  8. 8.
    Cochrane DR, Cittelly DM, Howe EN, Spoelstra NS, McKinsey EL, LaPara K, et al. MicroRNAs link estrogen receptor alpha status and Dicer levels in breast cancer. Horm Cancer. 2010;1(6):306–19.PubMedCrossRefGoogle Scholar
  9. 9.
    Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 2004;101(9):2999–3004.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Wilson RC, Tambe A, Kidwell MA, Noland CL, Schneider CP, Doudna JA. Dicer-TRBP complex formation ensures accurate mammalian microRNA biogenesis. Mol Cell. 2015;57(3):397–407.PubMedCrossRefGoogle Scholar
  11. 11.
    Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet. 2007;39(5):673–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Kumar MS, Pester RE, Chen CY, Lane K, Chin C, Lu J, et al. Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev. 2009;23(23):2700–4.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Abdelmohsen K, Tominaga-Yamanaka K, Srikantan S, Yoon JH, Kang MJ, Gorospe M. RNA-binding protein AUF1 represses Dicer expression. Nucleic Acids Res. 2012;40(22):11531–44.PubMedCentralPubMedGoogle Scholar
  14. 14.
    Tang KF, Ren H. The role of dicer in DNA damage repair. Int J Mol Sci. 2012;13(12):16769–78.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Papachristou DJ, Korpetinou A, Giannopoulou E, Antonacopoulou AG, Papadaki H, et al. Expression of the ribonucleases Drosha, Dicer, and Ago2 in colorectal carcinomas. Virchows Arch. 2011;459(4):431–40.PubMedCrossRefGoogle Scholar
  16. 16.
    Pampalakis G, Diamandis EP, Katsaros D, Sotiropoulou G. Down-regulation of dicer expression in ovarian cancer tissues. Clin Biochem. 2010;43(3):324–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med. 2008;359(25):2641–50.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Vaksman O, Hetland TE, Trope’ CG, Reich R, Davidson B. Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma. Hum Pathol. 2012;43(11):2062–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Zhao H, Jin X, Su H, Deng X, Fang Y, Shen L, Xie C. Down-regulation of Dicer expression in cervical cancer tissues. Med Oncol. 2014;31(5):937.PubMedCrossRefGoogle Scholar
  20. 20.
    Karube Y, Tanaka H, Osada H, Tomida S, Tatematsu Y, Yanagisawa K, et al. Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci. 2005;96(2):111–5.PubMedCrossRefGoogle Scholar
  21. 21.
    Khoshnaw SM, Rakha EA, Abdel-Fatah TM, Nolan CC, Hodi Z, Macmillan DR, et al. Loss of Dicer expression is associated with breast cancer progression and recurrence. Breast Cancer Res Treat. 2012;135(2):403–13.PubMedCrossRefGoogle Scholar
  22. 22.
    Grelier G, Voirin N, Ay AS, Cox DG, Chabaud S, Treilleux I, et al. Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype. Br J Cancer. 2009;101(4):673–83.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Yan M, Huang HY, Wang T, Wan Y, Cui SD, Liu ZZ, et al. Dysregulated expression of dicer and drosha in breast cancer. Pathol Oncol Res. 2012;18(2):343–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Avery-Kiejda KA, Braye SG, Forbes JF, Scott RJ. The expression of Dicer and Drosha in matched normal tissues, tumours and lymph node metastases in triple negative breast cancer. BMC Cancer. 2014;14:253.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Kwon SY, Lee JH, Kim B, Park JW, Kwon TK, Kang SH, et al. Complexity in regulation of microRNA machinery components in invasive breast carcinoma. Pathol Oncol Res. 2014;20(3):697–705.PubMedCrossRefGoogle Scholar
  26. 26.
    Tan L, Yu JT, Tan L. Causes and consequences of MicroRNA dysregulation in neurodegenerative diseases. Mol Neurobiol. 2014;51:1.PubMedGoogle Scholar
  27. 27.
    Wiesen JL, Tomasi TB. Dicer is regulated by cellular stresses and interferons. Mol Immunol. 2009;46(6):1222–8.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Torres A, Torres K, Paszkowski T, Jodłowska-Jędrych B, Radomański T, Książek A, et al. Major regulators of microRNAs biogenesis Dicer and Drosha are down-regulated in endometrial cancer. Tumour Biol. 2011;32(4):769–76.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Bennasser Y, Chable-Bessia C, Triboulet R, Gibbings D, Gwizdek C, Dargemont C, et al. Competition for XPO5 binding between Dicer mRNA, pre-miRNA and viral RNA regulates human Dicer levels. Nat Struct Mol Biol. 2011;18(3):323–7.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Kurzynska-Kokorniak A, Koralewska N, Pokornowska M, Urbanowicz A, Tworak A, Mickiewicz A, et al. The many faces of Dicer: the complexity of the mechanisms regulating Dicer gene expression and enzyme activities. Nucleic Acids Res. 2015;43(9):4365–80.PubMedCrossRefGoogle Scholar
  31. 31.
    Dedes KJ, Natrajan R, Lambros MB, Geyer FC, Lopez-Garcia MA, Savage K, et al. Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer. Eur J Cancer. 2011;47(1):138–50.PubMedCrossRefGoogle Scholar
  32. 32.
    Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dunning MJ, et al. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol. 2007;8(10):R214.PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Chiosea S, Jelezcova E, Chandran U, Acquafondata M, McHale T, Sobol RW, et al. Up-regulation of dicer, a component of the MicroRNA machinery, in prostate adenocarcinoma. Am J Pathol. 2006;169(5):1812–20.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Sugito N, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Kurehara H, et al. RNASEN regulates cell proliferation and affects survival in esophageal cancer patients. Clin Cancer Res. 2006;12(24):7322–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Chiosea S, Jelezcova E, Chandran U, Luo J, Mantha G, Sobol RW, et al. Overexpression of Dicer in precursor lesions of lung adenocarcinoma. Cancer Res. 2007;67(5):2345–50.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Ali Akbar Poursadegh Zonouzi
    • 1
  • Azim Nejatizadeh
    • 1
  • Mohammad Rahmati-Yamchi
    • 2
  • Hedieh Fardmanesh
    • 1
  • Samira Shakerizadeh
    • 1
  • Ahmad Poursadegh Zonouzi
    • 3
  • Kazem Nejati-Koshki
    • 4
  • Mohammad Shekari
    • 1
    Email author
  1. 1.Molecular Medicine Research CenterHormozgan University of Medical SciencesBandar AbbasIran
  2. 2.Drug Applied Research CenterTabriz University of Medical SciencesTabrizIran
  3. 3.Biotechnology Research CenterTabriz University of Medical SciencesTabrizIran
  4. 4.Department of Medical Nanotechnology, Faculty of Advanced Medical SciencesTabriz University of Medical SciencesTabrizIran

Personalised recommendations